Conroy O. Field

630 total citations · 1 hit paper
8 papers, 463 citations indexed

About

Conroy O. Field is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Conroy O. Field has authored 8 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 2 papers in Pathology and Forensic Medicine and 2 papers in Oncology. Recurrent topics in Conroy O. Field's work include Histone Deacetylase Inhibitors Research (2 papers), Protein Degradation and Inhibitors (2 papers) and Melanoma and MAPK Pathways (2 papers). Conroy O. Field is often cited by papers focused on Histone Deacetylase Inhibitors Research (2 papers), Protein Degradation and Inhibitors (2 papers) and Melanoma and MAPK Pathways (2 papers). Conroy O. Field collaborates with scholars based in United States and Switzerland. Conroy O. Field's co-authors include Dan A. Erkes, Andrew E. Aplin, Timothy J. Purwin, Edward J. Hartsough, Adam C. Berger, Weijia Cai, Emad S. Alnemri, Ulrich Rodeck, Corey Rogers and Ileine M. Sanchez and has published in prestigious journals such as Nature Communications, Blood and Cancer Discovery.

In The Last Decade

Conroy O. Field

7 papers receiving 460 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

2019 341 citations Dan A. Erkes, Weijia Cai et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Conroy O. Field

Since Specialization

Citations

This map shows the geographic impact of Conroy O. Field's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Conroy O. Field with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Conroy O. Field more than expected).

Fields of papers citing papers by Conroy O. Field

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Conroy O. Field. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Conroy O. Field. The network helps show where Conroy O. Field may publish in the future.

Co-authorship network of co-authors of Conroy O. Field

This figure shows the co-authorship network connecting the top 25 collaborators of Conroy O. Field. A scholar is included among the top collaborators of Conroy O. Field based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Conroy O. Field. Conroy O. Field is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Direct hemoglobin S polymerization inhibitor MCP435 completely halts ongoing disease pathophysiology in transgenic sickle cell disease mice 2025 ·Blood ·Andrew N. Fleischman, David R. Light, Kandace Gollomp, Conroy O. Field, (unknown), (unknown), (unknown), (unknown), Shaomei Sun, R. Clark Brown, (unknown), Osheiza Abdulmalik	0
2	Platelet integrin αIIbβ3 plays a key role in a venous thrombogenesis mouse model 2024 ·Nature Communications ·Brian D. Adair, Conroy O. Field, José Luís Izquierdo Alonso, Jian-Ping Xiong, Shi‐Xian Deng, (unknown), (unknown), Clary B. Clish, (unknown), Mark Yeager, Youzhong Guo, David A. Tess, Donald W. Landry, Mortimer Poncz, M. Amin Arnaout	5
3	Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors 2020 ·Cancer Immunology Research ·Jessica L.F. Teh, Dan A. Erkes, Phil F. Cheng, Manoela Tiago, Nicole A. Wilski, Conroy O. Field, Inna Chervoneva, Mitch P. Levesque, Xiaowei Xu, Reinhard Dummer, Andrew E. Aplin	13
4	Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis breakdown → 2019 ·Cancer Discovery ·Dan A. Erkes, Weijia Cai, Ileine M. Sanchez, Timothy J. Purwin, Corey Rogers, Conroy O. Field, Adam C. Berger, Edward J. Hartsough, Ulrich Rodeck, Emad S. Alnemri, Andrew E. Aplin	341
5	The next‐generation BET inhibitor, PLX51107, delays melanoma growth in a CD8‐mediated manner 2019 ·Pigment Cell & Melanoma Research ·Dan A. Erkes, Conroy O. Field, Claudia Capparelli, Manoela Tiago, Timothy J. Purwin, Inna Chervoneva, Adam C. Berger, Edward J. Hartsough, Jessie Villanueva, Andrew E. Aplin	23
6	PLX3397 inhibits the accumulation of intra‐tumoral macrophages and improves bromodomain and extra‐terminal inhibitor efficacy in melanoma 2019 ·Pigment Cell & Melanoma Research ·Dan A. Erkes, Sheera R. Rosenbaum, Conroy O. Field, Inna Chervoneva, Jessie Villanueva, Andrew E. Aplin	11
7	Testis-specific ATP synthase peripheral stalk subunits required for tissue-specific mitochondrial morphogenesis in Drosophila 2017 ·BMC Cell Biology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Conroy O. Field, (unknown), M. Grace Gordon, (unknown), (unknown), Cricket G. Wood, Margaret T. Fuller, Karen G. Hales	30
8	Processing of miR17-92 Cluster in Hepatic Stellate Cells Promotes Hepatic Fibrogenesis During Alcohol-Induced Injury 2016 ·Alcoholism Clinical and Experimental Research ·Elizabeth Brandon‐Warner, (unknown), Catherine R. Culberson, Conroy O. Field, Andrew S. deLemos, Mark W. Russo, Laura W. Schrum	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact